# A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

> **NCT00594555** · PHASE2 · WITHDRAWN · sponsor: **University of Cincinnati** · enrollment: 20 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia, Blast Crisis
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib Mesylate
- **DRUG:** CLAG

## Key facts

- **NCT ID:** NCT00594555
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-11
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Principal Investigator resigned position with the University of Cincinnati, closing study at this site will reopen study in new position
- **Last updated:** 2008-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00594555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00594555, "A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00594555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*